An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee

Labopharm

Status and phase

Completed

Phase 3

Conditions

Osteoarthritis, Knee

Treatments

Drug: Tramadol Once A Day

Study type

Interventional

Funder types

Industry

Identifiers

NCT00833911

MDT3-004

NCT00833911 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to collect information regarding the long-term (6 and 12 months) safety of Tramadol HCl Once-A-Day(OAD) 300 mg.

Enrollment

392 patients

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis of the knee consistent with the American College of Rheumatology (ACR) Clinical Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1991):
- Current knee pain,
- Less than 30 minutes of morning stiffness with or without crepitus on active motion,
- Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within two years prior to entry into the study.
Erythrocyte Sedimentation Rate (ESR) < 40 mm/hour.
Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale total score of >= 150 mm at baseline. (5 questions/100 mm scale each with an averaged response of 30 mm or higher per question).
Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.
The Patient has signed and dated the Research Ethics Board (REB) approved, written, informed consent prior to study participation.

Exclusion criteria

Known rheumatoid arthritis or any other rheumatoid disease.
Secondary arthritis i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations.
Obesity Class II (Body Mass Index (BMI) >= 35) (National Institutes of Health (NIH), 2000).
Major illness requiring hospitalization during the 3 months before commencement of the screening period.
Patients who are unwilling to stop taking pain medication other than the study medication (for arthritis or other types of pain) or are unwilling to stop taking other medications for the treatment of osteoarthritis (OA).
Patients who have previously failed tramadol hydrochloride (HCl) therapy or those who discontinued tramadol HCl due to adverse events.
Patients who are taking or within the last 3 weeks have taken the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.
Patients who are taking or have taken another investigational agent within the last 30 days.
Patients with a history of seizure disorder other than Infantile Febrile Seizures.
Patients who are opioid dependent.
Patients with bowel disease causing malabsorption.
Patients who are pregnant or lactating or patients of child-bearing potential who are unwilling to utilize a medically approved method of contraception during participation in this clinical trial.
Patients with significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.
Patients with significant renal disease, defined as creatinine clearance <30 mL/min as estimated by the method of Levey et al., 1999.
Current substance abuse or dependence, other than nicotine.
Allergy or adverse reaction to tramadol or any structurally similar drugs e.g. opiates.
Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.